<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394381</url>
  </required_header>
  <id_info>
    <org_study_id>CIK#1/2006</org_study_id>
    <nct_id>NCT00394381</nct_id>
  </id_info>
  <brief_title>Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome</brief_title>
  <official_title>Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I/II study to explore the feasibility and efficacy of autologous CIK cells in
      patients with acute myeloid leukemia (AML)/ high grade myelodysplastic syndrome (MDS)

        1. Group 1: As adjuvant therapy in minimal residual disease state after autologous PBSCT.

        2. Group 2: As an adoptive immunotherapy in untreated disease state when conventional
           therapy with curative intent is not applicable
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I /II study on the feasibility / efficacy of adoptive immunotherapy with
      autologous CIK cells for the following 2 groups of patients who have AML or high grade MDS :

        1. Group 1 patients in minimal residual disease state post autologous peripheral blood stem
           cell transplant ( PBSCT ), and

        2. Group 2 patients with untreated high grade MDS or AML, who are not fit for standard
           curative intent chemotherapy.

      The CIK cells will be generated by leukapheresis from patients and cultured in GMP
      facilities. Four repeated infusions will be given for a target dose of 1x10e10 T cell per
      infusion.

      Efficacy will be assessed by

        1. Disease free survival compared to historical control in group 1 given CIK cells post
           autologous PBSCT as adjuvant immunotherapy (n=20 over 3 years), and

        2. Effect on the peripheral or marrow leukemia cell load in group 2 patients given CIK
           cells as alternative therapy in place of chemotherapy (n=10).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood count changes</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T lymphocyte subsets</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell functions</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse reactions</measure>
    <time_frame>24 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome, High Grade</condition>
  <arm_group>
    <arm_group_label>CIK infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of autologous CIK cells in study group. There is only one arm to this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infusion of autologous CIK cells</intervention_name>
    <description>Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients</description>
    <arm_group_label>CIK infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For Group 1: AML or MDS post autologous peripheral blood or marrow stem cell
             transplant.

          2. For Group 2: High grade MDS ( RAEB or RAEBIT ) or AML, whom the haematologist in
             charge has assessed and deemed unfit for chemotherapy with curative intent.Patients
             must have fairly stable white cell count requiring only low dose or no
             myelosuppressive medication

          3. Patients must understand the trial nature of this treatment and accept the possible
             absence of benefit.

        Exclusion Criteria:

          1. uncontrolled infection

          2. life expectancy less than 6 weeks.

          3. Contraindication to undergo one session of leukapheresis for PBMNC harvesting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeh-Ching Linn, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002 Jan;116(1):78-86.</citation>
    <PMID>11841399</PMID>
  </reference>
  <reference>
    <citation>Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7.</citation>
    <PMID>15744236</PMID>
  </reference>
  <reference>
    <citation>Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999 Nov;81(6):1009-16.</citation>
    <PMID>10576658</PMID>
  </reference>
  <reference>
    <citation>Jiang H, Liu KY, Tong CR, Jiang B, Lu DP. [The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia]. Zhonghua Nei Ke Za Zhi. 2005 Mar;44(3):198-201. Chinese.</citation>
    <PMID>15840260</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>autologous CIK cells</keyword>
  <keyword>autologous peripheral blood stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

